家/TB/消息

07/11/19

“改变游戏规则”的结核病疫苗在试验中显示出希望

TB Xray - Main
Medical staff at an X-Ray unit which enables patients with TB to be detected more quickly. Now, an experimental TB vaccine promises to stop the disease from spreading to the lungs for three years. Copyright:ausaid

速度阅读

  • 大约5％至百分之十的潜在结核病患者一生都患上了这种疾病
  • Trial shows a vaccine could prevent people with latent TB from developing it over three years
  • 尽管取得了令人鼓舞的结果，但仍需要更多的研究来帮助影响决策

By:纳尔逊·曼德拉Ogema

重新出版

我们鼓励您在线重新发布本文，并在我们的Creative Commons归属许可下免费发布，但请遵循一些简单的准则：
  1. You have to credit our authors.
  2. 您必须信贷scidev.net-在可能的情况下包括我们的徽标，并带有回到原始文章的链接。
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. 如果你想也发表在这个图像story you will need to confirm with the original source if you're licensed to use them.
  5. 在您的网站上获取文章的最简单方法是嵌入以下代码。
有关更多信息，请查看我们的媒体页面并重新发布指南.

The full article is available here as HTML.

按CTRL-C复制

寄给朋友

您在此页面上提供的详细信息将不会用于发送未经请求的电子邮件，也不会出售给第三方。请参阅隐私政策。

[内罗毕]一个实验tuberculosis (TB)vaccine could prevent people who have TB with no sign of illness from progressing to TB of the lungs for up to three years, potentially saving millions of lives, a学习shows.

世卫组织报道说，世界人口的四分之一被结核病感染结核分枝杆菌但是没有主动结核的迹象疾病and do not feel ill — a phenomenon called latent TB. About five to ten per cent of those with latent TB develop active tuberculosis disease in their lifetime.

据世卫组织说，通常影响肺部的结核病是全球十大杀手。2018年，大约1000万人因结核病生病，结果有150万人死亡。

“The M72/AS01E vaccine was well tolerated and offered 50 per cent protection against development of pulmonary [lung] TB.”

Mark Hatherill, University of Cape Town, South Africa

该疫苗称为M72/AS01E，由制药公司GlaxoSmithkline生物学和AERAS开发，在2014年8月至2018年11月从肯尼亚，南非和赞比亚的3,575名成年人进行了试用。他们的病情已有三年。

Mark Hatherill, a co-author of the study published in the新英格兰医学杂志上周（10月29日）说，该研究表明，可以通过接种先前感染的个体来防止结核病，并将其描述为“全球结核病控制工作的潜在改变游戏规则”。

“The M72/AS01Evaccine was well tolerated and offered 50 per cent protection against development of pulmonary [lung] TB for at least three years, when given toHIV-uninfected他说，患有“潜在”结核病感染的成年人。

随机分配参与者接受两剂M72/AS01Eor placebo, administered one month apart.

如果在包括不同的地理位置，祖先，年龄和风险群体在内的更多样化的人群中，疫苗的结果是一致的，那么可以挽救数百万的生命，这是可以挽救的。

“Funderswill be needed to support the next stage of trials to confirm these exciting results in a larger and more diverse population,” he toldSciDev.Net.

现有的结核病疫苗BCG仅对儿童有部分效果，并为成年人提供不良保护。

肯尼亚Eldoret的Fountain Health Care医院的传染和热带疾病顾问Paul Yonga告诉SciDev.Netthat the results of the study were promising given the large sample size.

他指出，50％的疗效和三年的保护达到了推荐的结核病疫苗的WHO阈值，但说得出的结论还为时过早。

“For now, I think the results presented are quite interesting and encouraging but are still not good enough to influence policy from a public health perspective,” he added.

You might also like

潜在的突破是上周预防结核病的两个主要发展之一。制药公司Sanofi宣布其预防性结核病患者的价格下降了近70％。

The deal, negotiated by Unitaid and the Global Fund to Fight Aids, Tuberculosis and Malaria, will make a three-month course of treatment available in 100 low- and -middle-income countries for US$15, compared with the previous cost of US$45.

This piece was produced by SciDev.Net’s Sub-Saharan Africa English desk.

References

Dereck R. Tait and othersFinal Analysis of a trial of M72/AS01E vaccine to prevent tuberculosis（新英格兰医学杂志，2019年10月29日）